News Ottimo raises $140m for its PD-1/VEGF cancer drug Ottimo raises $140m for PD-1 and VEGF-targeting jankistomig, which the startup says is differentiated from bispecific antibodies in the class.
Oncology Sponsored 12 Questions with Mimi Huizinga Dr Mimi Huizinga is Vice President, Oncology Medical Affairs, Lung Cancer at AstraZeneca.
News End of the line for MSD's TIGIT, LAG-3 cancer drugs MSD has stopped development of anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline.
News FDA dents J&J's blockbuster hopes for Rybrevant FDA has sent a complete response letter to J&J, denying approval of its subcutaneous version of lung cancer therapy Rybrevant.
Oncology Sponsored Addressing the oncological ‘other’: How predictive analysis ... In a new report, ‘Helping others: unlocking the potential of
News Why is colorectal cancer rising in younger age groups? A study has confirmed that colorectal cancer is rising in younger adults around the world, with England among countries seeing the fastest rise.
News PBM reform dropped in Congress' funding package Proposed reforms to the regulations for PBMs were dropped from the US Congress' end-of-year bill to provide funding to the federal government.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.